Retatrutide:NewlyWeightLossPeptide
-ByPhcokercom
Retatrutidepeptide:
Sequence:
MolecularFor
mula: C223H343F3N46O70
MolecularWe
ight: 4845.444g/mol
PubChemCI
D: 474492335
CASNumber:2381089-83-2
Synonyms: LY3437943
RetatrutidepeptideisaweightlossdrugdevelopedbyEliLillyandCompanyi ntheUnitedStatesforthetreatmentofobesity.Itisatriplehormonerecepto ragonistofGLP-1,GIPandglucagonreceptorsIts"TripleG"effectmakesits
weightlossresultsmoreeffectivethanothercompetitors.Intrials,itshowedin credibleweightlossresults,helpingpatientslose24%oftheirbodyweightin 48weeksThesearethehighestresultseverseenwithananti-obesitydrugTh isisencouragingnewsformanypeoplewhohaveeffectivelygivenuptryingt oloseweight
WhatIsRetatrutidePowder?
Obesityisatreatable,chronicdiseasewhosebiologicalbasisiscomplex.Resear chersarecurrentlyinthefieldofrapidlyexpandingtreatmentstoprovidepote ntiallyhighlyeffectivetreatmentoptionsforobesepatients.
Recently,RetatrutidepowderdevelopedbyEliLillyhasreceivedwidespreadatt entionfromthemarket.ThisinjectabledrugisalsoknownasGGGtri-agonist, GLP-1/GIP/glucagontri-agonist,orLY3437943.
RetatrutidebelongstotheGLP-1familyalongwithweightlossdrugssuchas SemaglutideandTirzepatide.However,therearedifferencesbetweenthesethre eproductsSemaglutidetargetsonlyahunger-controllinghormonecalledGLP1,whileTirzepatidetargetsbothGLP-1andGIPRetatrutidetakesweightlosst othenextlevelbytargetingthreehunger-regulatinghormones:GIP,GLP-1,an dglucagonreceptors.
ResearcherswhospecializeinweightlosspeptideshasbeengreatinterestinR etatrutide.Todomorein-depthresearch,theypurchasedRetatrutidepowderfr omtheretatrutidepowdermanufacturersonline,mainlyfocusingontheeffects, benefits,andcomparisonofRetatrutidewithSemaglutideandTirzepatideAs amoreadvancedweightlosspeptide,Retatrutideisundoubtedlymoreexpensi vethanSemaglutideandTirzepatide.AlthoughitwillbecheapertobuyRetatr
utideonline,itisimportanttochooseareliablesupplier.
StructureofRetatrutide
HowDoesRetatrutideWork?
Whatarereceptoragonists?
Receptorsareproteinentitiesthatdecoratetheoutsideofourcellsandareco nduitsforsignalsfromoutsidethecellAfterbinding,thesesubstancessendm essagestoourspecificcells,stimulatingtherelevantorganstorespond[2][10]
Anagonistisacompound,eitheradrugorachemical,thatbindstoacellre ceptorandproducesaspecificresponse.Itcanbeeithernaturallyoccurringor synthetic.Themosttypicalexamplesofnaturalagonistsarehormonesandne urotransmitters.
Retatrutide’smechanismofaction:
Differentreceptoragonistsplaydifferentrolesinourbodies,dependingonthe cellreceptortheybindto.Asmentionedpreviously,Retatrutidestimulatesglu cagon,GLP-1,andGIPreceptoragonists.Understandingagonistsisthefirstste pinunderstandinghowRetartrutideworks.Here'swhateachdoesinourbodi
esandwhytheyhelpwithweightloss:
GLP-1(glucagon-likepeptide-1):
Theintestinalpeptidehormoneglucagon-likepeptide-1(GLP-1)isobtainedby ourbodiesfromthefoodweeat.Thishormonehasmanyuses,butitsmainr oleistocontrolfoodintakeandhunger.Whenweeatamealorsnack,blood sugarrises,whichpromptsthereleaseofGLP-1,whichpromptsthepancreas tosecreteinsulin.
Insulinisanimportanthormoneproducedbyourbodiesandiskeyinreleasin gtheglucosewetakeinfromourdietintoourcellsCellsrelyonglucoseas theirmainenergysource,whichhighlightstheimportantroleofinsulin.Lacko fenoughinsulinpreventsglucosefromenteringcells,whichnotonlyblocksn utrientabsorptionbutalsocausesbloodsugartorise,leadingtoweightgain.
GLP-1promotesinsulinsecretionfromthepancreaswhilereducingglucoserele asefromtheliver.Inadditiontoregulatingbloodsugar,GLP-1alsointentionall yreducesgastricemptying,therebyprolongingdigestionThismeansyou'llfee lfullfasterafteramealAdditionally,GLP-1affectsthebrain'shungercenter, whichcanleadtoadecreaseinappetite.ThesetwopartsofGLP-1interactto quellhunger.Thiseffectissimilartoappetitesuppressantssuchasphentermi ne,whicharecommonlyusedforweightloss.
GIP(glucose-dependentinsulinotropicpolypeptide):
Glucose-dependentinsulinotropicpolypeptide(GIP)belongstotheincretinhor monefamily,likeGLP-1.Therefore,thesetwopeptidehormonesbehaveinvery similarways.Thishormoneisproducedinthesmallintestineafteramealan
dresidesonpancreaticbetacells,effectivelyinitiatingthereleaseofinsulin.Th isfeaturehelpscontrolbloodsugaraftermeals.However,theGIP'sresidencet imeinoursystemisveryshort,about7minutesGIPagonistdrugslikeMoun jaroworkbymaintainingGIPlevelsinthebloodtoprolongitspresenceThis hormonecausesthestomachtoslowlyemptywhilereducingappetiteThisisw hythestomachisoneofthebestplacestoinjectTirzepatideforweightloss.
Glucagonreceptor:
Glucagonisanothervitalhormonethatplaysanimportantroleinregulatingb loodsugarlevels.Itcomesfromthepancreas,similartoGLP-1andGIP,butit comesfromaspecifictypeofcellcalledalphacellsGlucagonworksintheex actoppositewaytotheabovehormones.Whenbloodsugarlevelsdropduet ofactorssuchasfastingorsleep,glucagonbeginsconvertingglycogen(retain edsugar)intoglucose.Thisprovidesourbodieswitheasilyavailablefuel.Alth oughinsulinandglucagonperformdifferenttasks,theyworktogethertomain tainoptimalbloodsugarlevels.Insulindirectssugarintoglycogen,whilegluca gondirectssugarintoglycogen.
Howdoesglucagonhelpwithweightloss?
Oursystemstoresexcessglucosefromdietaryintakeasfatandglycogen.Whe nwedon'tconsumecarbohydrates(suchasduringsleep,alow-caloriediet,or intermittentfasting),glucagonbeginsworkingtocontrolglucoseproduction. Onceglycogenstoresaredepleted,glucagonswitchestobreakingdownfatst ores,convertingthemintoenergy.
WhatAreTheCoreRegistrationStudiesForRetatrutide?
SinceRetatrutidewaslaunched,ithasbeensoughtafterbymanyweightlosspeople andscientificresearchers.PeopleevenbuyRetatrutidetoconductmorein-depth researchtobetterunderstandtheamazingeffectsofRetatrutide.Theprimary studiesforretatrutideare:
TRIUMPH-1:Randomized,double-blind,placebo-controlledtrialtostudyefficacy andsafetyinobeseoroverweightparticipantswithouttype2diabetes,including thosewithOSAandOA
TRIUMPH-2:Randomized,double-blind,placebo-controlledtrialtostudyefficacy andsafetyinobeseoroverweightpatientswithtype2diabetes,includingthosewith OSA
TRIUMPH-3:Randomized,double-blind,placebo-controlledtrialdesignedto investigateclassII(BMI≥35kg/m2and<40kg/m2)orclassIII(BMI≥40kg/m 2)participantsEfficacyandSafetym2)ObesityandEstablishedCardiovascular Disease
TRIUMPH-4:Randomized,double-blind,placebo-controlledtrialtostudyefficacy andsafetyinobeseoroverweightOAparticipants
WhatAreTheClinicalResultsOfRetatrutide?
PhaseIItrial
ThelatestresultsfromthephaseIItrial(NCT04881760)showedthatafter48weeks, thepercentagechangeinbodyweightwas-8.7%,-17.1%,-22.8%and-24.2%.
Additionally,thestudyfoundthat60%ofparticipantslostmorethan15%oftheir bodyweight.Fromasafetyperspective,themostcommonsideeffectsareofa gastrointestinalnatureTherefore,thesafetyprofileofretarglutideisthesameas thatofotherincretin-basedtreatments.
PhaseIIItrial
APhaseIIItrial(TRIUMPH-3;NCT05882045)beganinMaytoevaluatetheeffectsof retarglutideinpatientswithestablishedcardiovasculardiseaseandthosewithsevere obesityThetrialisexpectedtoendinNovember2025
WhatAreTheBenefitsOfRetatrutide?
Semaglutide,TirzepatideandRetatrutide,asthethreegiantsintheweightlossworld, aredeeplylovedbypeopleandareoftencomparedtogether.Sowhatarethe differencesandsimilaritiesamongthem?WhyRetatrutideismoreexpensivethan
SemaglutideandTirzepatide?
RetatrutidevsTirzepatidevsSemaglutide
Researchonretatrutideisstillongoing.However,currentclinicaltrialsshowthat
RetatrutidepromotesweightlossbetterthanSemaglutideandTirzepatide.Hereare someclinicaltrialdataforreference:
NovoNordisk'sSemaglutidewasfoundtoresultinanaverageweightlossofabout 15%,orabout34pounds,after68weeks.
AnotherweightlossdrugfromEliLillyandCompany,Tirzepatide,wasshownto reducebodyweightbyanaverageof225%after72weeks
After48weeks,theexperimentaldrugRetartutidehelpedpeopleloseanaverageof 24percent,theequivalentof58pounds.However,theactualeffectivenessof
RetatrutidemaybebetterbecauseitislimitedtotimePhase3trialswill demonstrateitsfullpotentialandlong-termimpact,makingiteasierforpeopleto believeinit
Sincethesedrugshavenotbeendirectlycomparedinhead-to-headclinicaltrials,it issafetosaythatthesecomparisonswillnotbedirectcomparisonsRetatrutide powderistheactiveingredientofretatrutideinjection,whichcanhelpwithweight lossandtreattype2diabetes.Nonetheless,Retatrutidemaybefasterandmore effectivethanTirzepatideandSemaglutide.
Retatrutideeliminatesfatintheliver
Withthedevelopmentoflivingstandardsandtechnology,obesityhasbecomea seriouspublichealthproblem,anditcanalsoleadtootherdiseases,suchastype2 diabetes,liverdisease,cardiovasculardisease,andhypertension.Accordingto research,morethan33millionpeopleintheUnitedStateshavetype2diabetes Amongthem,5%-7%ofpeoplesufferfromclinicallysignificantliverdisease.
HepatologistsatVirginiaCommonwealthUniversitysaythatmorethan85percent ofobeseparticipantswithfattyliverdiseaseinclinicaltrialsoftheexperimentaldrug Retatrutidehadtheirliverfatreducedtothepointwheretheywerenolonger diagnosedasfattyliverdisease.
RetatrutidetargetsandactivatesGIP,GLP-1andglucagonreceptors,whichare closelyrelatedtocontrollinghungerandsatiety.Theycanhelppeoplefeelfuller longeraftereating.Regulatesbloodsugarlevels,therebyaidingweightloss.
Itisworthnotingintheexperimentthatbythe48thweekoftheexperiment,an astonishing93%ofthepatientswhotookthehigherdosehadreducedtheirliverfat tolessthan5%.Theexperimentalresultssuggestthatretatrutidemaybecomean extremelyeffectivetreatmentforhigh-riskpatients,preventingtheprogressionof liverdiseaseandpotentiallyreversingthedisease.Thesignificanceofthisstudywith retatrutideisthatpatientscanusethisdrugtoeliminatefatintheearlystagesofthe disease,therebyavoidingitcausingsubstantialdamagetotheliver,andalsoreduce long-termcardiac,metabolic,renalandhepaticdamage.damage.
AftercheckthereviewofRetatrutide,TirzepatideandSemaglutide,Retatrutide showedsuperiorweightlosseffects.Butindividualorresearchersseekingretatrutide
forweightmanagementpurposefoundthatretatrutidepriceismuchexpensivethan semaglutideandtirzepatide,althoughbuyretatrutidefromsomepeptide manufacturersonline.Soindividualseekinglong-termweightmanagementpreferto buytirzepatideandsemaglutide.Especiallybuyonline,becausethecheaperprice andfastshipping,easyorderprocess.
WhatAreTheSideEffectsOfRetatrutide?
Retatrutidepeptideisasyntheticpeptide,primarilyavailableintheformofraw powderandfinishedvials.SupplierPhcokerDespiteitshighefficacy,Retatrutidehas shownstrongweightlossbenefits,butitspotentialsideeffectsmustalsobe consideredRetatrutidealsocarriessomerisksofadversereactions
AswithotherGLP-1weightlossdrugs,themostcommonsideeffectofretatrutideis gastrointestinaldiscomfort,including:
constipate
nausea
diarrhea
Vomit
Insomecases,duetopersonalconstitution,usersmayexperienceheadachesasa resultofitssideeffects,andiftheheadachesworsen,theymayneedpainkillersto relievethem.
Ifyouloseweightquickly(morethan10poundspermonth)whiletakingRetatrutide, youmaybeatriskofdevelopinggallstones
Retatrutidemayalsoaffectthyroidfunction,causingchangesinthyroidhormones. Inaddition,anincreasedriskofhypoglycemiamaybeassociatedwithretatrutide, particularlyinpeoplewithdiabetesItisverynecessarytopaycloseattentionto bloodsugaratthistime.
WhenusingRetatrutide,patientsshouldbeawareofthesepotentialsideeffectsand promptlyinformtheirhealthcareprofessional.
IsRetatrutidePowderAvailable?
RetatrutideiscurrentlyinPhaseIIIclinicaltrials,awaitingapprovalfromtheUS FoodandDrugAdministration,andthistrialisexpectedtocontinueuntil2025.
Retatrutide,asatriplereceptoragonist,showsamorepowerfulweightlosseffect thanTirzepatideandSemaglutide,makingmanyobesepatientseagertotryit.
AfterseeingtheresultsofthePhaseIItrialofRetatrutide,manypeptide manufacturersappearedonthemarkettryingtoproduceRetatrutidepowder.Now thereareRetatrutidepowderforsaleonline.Relevantresearchersmayhavedoubts
aboutthequalityofRetatrutidesuppliers.Ifyouwanttotestthequalityof Retatrutidepowder,youcanfirstbuythecheaperRetatrutidelyophilizedpowderfor testingPhockercomcansupplyyouwithhighqualityRetatrutiderawpowderand lyophilizedpowderinvialsform.
RetatrutideManufacturer丨WhereToBuyRetatrutide Peptide?
RetatrutideisanewweightlossproductdevelopedbyEliLillyandCompany.A mid-stageclinicaltrialshowsthatRetatrutidecanhelpobesepatientslosean averageof24%oftheirweight.AlargerphaseIIIclinicaltrialconfirmedthepowerful
weightlosseffectofRetatrutide,anditmaysurpassTirzepatidetobecomea better-sellingweightlossproduct.
PhcokerisoneofthesuppliersandmanufacturersofRetatrutide.Weregularly supplyRetatrutideintwoforms:originalpowderandlyophilizedpowderinvials.The regularspecificationsofvialsare5mgand10mgWealsosupportcontract customizationandproductiontomeetyourdifferentneeds.Feelfreetocontactus anytime.
F&QAboutRetatrutide
WhatisEliLilly’slatestweight-losspeptide?
Retatrutide.RetatrutideisthelatestpowerfulweightlossdruglaunchedbyEliLilly andCompany.ItsweightlosseffectevenexceedsthatofTirzepatide,anditcanhelp obesepatientsloseanaverageof24%oftheirweight.
WhatisRetatrutide?
Reattrutideisatriplereceptoragonist-GIP,GLP-1andglucagonreceptors.Currently awaitingFDAapproval.Cansignificantlypromoteweightlossinobesepatients.
WhyisRetatrutideundergoingclinicalstudies?
ThepurposeofthestudyoftheRetatrutidepeptideistoevaluateitsefficacyand safetyinpatientswithobesityandestablishedcardiovasculardisease.Asfarasthe currentexperimentalresultsareconcerned,Retatrutideshowsamoresignificant effectthanitscontrolgroupItcanbesaidtobeanupgradedversionofRetatrutide andTirzepatide.
WhatareGGGtri-agonists?
Retatrutide,alsoknownasGGGtri-agonist,issonamedbecauseitactsasanagonist onthreereceptors:GIP,GLP-1andglucagonreceptors
WhatisthedifferencebetweenRetatrutideandTirzepatide?
Asatriplereceptoragonist,RetatrutideismorepotentthanTirzepatide.
①Comparisonofactionmechanisms:
Retatrutideachievesitsintendedweightlosseffectsprimarilybytargetingthree hunger-regulatinghormones:GIP,GLP-1,andglucagonreceptors.
TirzepatidesuppressesappetitethroughGLP-1andGIP,therebypromotingweight
②Comparisonofweightlosseffects:
Retatrutide-Accordingtorelevantclinicaltrials,Retatrutidecanhelpobesepatients loseapproximately24%oftheirweightwithin48weeks.Comparedwithother weightlossdrugs,Retatrutidecanachievemorepowerfuleffects
Tirzepatide-Studieshaveshownthatatthelowestdose,itcanleadto5%weight loss,andatthehighestdose,itcanreduce22%at72weeks
IsRetatrutideapprovedbytheFDA?
notyetRetatrutideiscurrentlyinPhaseIIIclinicaltrialsandhasnotyetbeen approvedbytheFDA.
IsthereabrandnameforRetatrutide?
SinceRetatrutideisstillunderresearchandhasnotbeenapprovedbytheFDA,it doesnothaveatradenameThecurrentofficialnameisstillRetatrutide WhatarethebenefitsofRetatrutide?
①PromoteweightlossbyactingonGIP,GLP-1andglucagonreceptors;
②Effectivelymanagetype2diabetes;
③Preventfattyliverdiseaserelatedtometabolicdysfunction.
IsRetatrutidereallyeffectiveatpromotingweightloss?
YES!!!
Retatrutideboostedaverageweightlossby24%at48weeks,accordingtointerim results
DoesRetatrutidehaveanysideeffects?
YES
ThesideeffectsofRetatrutidearegenerallyconsistentwithotherweightlossdrugs, mainlygastrointestinalsideeffects,andmaybeaccompaniedbynausea,vomiting, diarrhea,constipationandotheradversereactionsduringuse.However,these reactionswillgraduallydisappearwithtimeofuse.
WouldyoujumpfromSemaglutidetoRetatrutideafterRetatrutideisapproved?
Somepatientssaidtheywouldnotbecauseitwastooexpensive.
Somepatientssaidtheywouldswitchtoitbecausecurrentresearchshowsthatits
weightlosseffectisindeedbetterthanotherweightlossdrugs
Theremainingpeoplearestillhesitant,worriedthatthispowerfulweightlossdrug willcauseharmtothebody.
CanIgetaprescriptionforRetatrutide?
ItshouldbenotedthatRetatrutideiscurrentlyaninvestigationaldrugunder investigation.Thismeansthatnoprescriptioncanbegiventoyouatthis time.OzempicandWegovyarebothontheFDA'sDrugShortageslistasofMay2023.
Whenadrugisinlowsupply,compoundersmaybeabletomanufacturea compoundedversionofthatdrugiftheymeetspecificrequirements.
ReferencesCitations:
1JastreboffAM,AronneLJ,AhmadNN,WhartonS,ConneryL,AlvesB,Kiyosue A,ZhangS,LiuB,BunckMC,StefanskiA;SURMOUNT-1Investigators."Tirzepatide OnceWeeklyfortheTreatmentofObesity"NEnglJMed2022Jul21;387(3):205-216 doi:10.1056/NEJMoa2206038.Epub2022Jun4.PMID:35658024
2FríasJP,DaviesMJ,RosenstockJ,PérezManghiFC,FernándezLandóL, BergmanBK,LiuB,CuiX,BrownK;SURPASS-2Investigators."Tirzepatideversus
SemaglutideOnceWeeklyinPatientswithType2Diabetes"NEnglJMed2021Aug 5;385(6):503-515.doi:10.1056/NEJMoa2107519.Epub2021Jun25.PMID:34170647
3RosenstockJ,WyshamC,FríasJP,KanekoS,LeeCJ,FernándezLandóL,Mao H,CuiX,KaranikasCA,ThieuVT."EfficacyandsafetyofanoveldualGIPandGLP-1 receptoragonisttirzepatideinpatientswithtype2diabetes(SURPASS-1):a double-blind,randomised,phase3trial"Lancet2021Jul10;398(10295):143-155doi: 10.1016/S0140-6736(21)01324-6.Epub2021Jun27.PMID:34186022
4SyedYY."Tirzepatide:FirstApproval."Drugs.2022Jul;82(11):1213-1220.doi: 10.1007/s40265-022-01746-8.PMID:35830001
5KaragiannisT,AvgerinosI,LiakosA,DelPratoS,MatthewsDR,TsapasA, BekiariE"Managementoftype2diabeteswiththedualGIP/GLP-1receptoragonist tirzepatide:asystematicreviewandmeta-analysis."Diabetologia.2022
Aug;65(8):1251-1261.doi:10.1007/s00125-022-05715-4.Epub2022May17.PMID: 35579691
6ThomasMK,NikooienejadA,BrayR,CuiX,WilsonJ,DuffinK,MilicevicZ, HauptA,RobinsDA"DualGIPandGLP-1ReceptorAgonistTirzepatideImproves Beta-cellFunctionandInsulinSensitivityinType2Diabetes."JClinEndocrinolMetab. 2021Jan23;106(2):388-396.doi:10.1210/clinem/dgaa863.PMID:33236115
7MinT,BainSC."TheRoleofTirzepatide,DualGIPandGLP-1ReceptorAgonist,
intheManagementofType2Diabetes:TheSURPASSClinicalTrials"DiabetesTher 2021Jan;12(1):143-157.doi:10.1007/s13300-020-00981-0.Epub2020Dec15.PMID: 33325008
8DahlD,OnishiY,NorwoodP,HuhR,BrayR,PatelH,RodríguezÁ."Effectof SubcutaneousTirzepatidevsPlaceboAddedtoTitratedInsulinGlargineonGlycemic ControlinPatientsWithType2Diabetes:TheSURPASS-5RandomizedClinical Trial."JAMA.2022Feb8;327(6):534-545.doi:10.1001/jama.2022.0078.PMID: 35133415
9DelPratoS,KahnSE,PavoI,WeerakkodyGJ,YangZ,DoupisJ,AizenbergD, WynneAG,RiesmeyerJS,HeineRJ,WieseRJ;SURPASS-4Investigators."Tirzepatide versusinsulinglargineintype2diabetesandincreasedcardiovascularrisk (SURPASS-4):arandomised,open-label,parallel-group,multicentre,phase3 trial."Lancet.2021Nov13;398(10313):1811-1824.doi:
10.1016/S0140-6736(21)02188-7.Epub2021Oct18.PMID:34672967
10ChavdaVP,AjabiyaJ,TeliD,BojarskaJ,ApostolopoulosV."Tirzepatide,aNew EraofDual-TargetedTreatmentforDiabetesandObesity:AMini-Review"Molecules 2022Jul5;27(13):4315.doi:10.3390/molecules27134315.PMID:35807558
11WillardFS,DourosJD,GabeMB,ShowalterAD,WainscottDB,SuterTM, CapozziME,vanderVeldenWJ,StutsmanC,CardonaGR,UrvaS,EmmersonPJ,Holst
www.phcoker.com
JJ,D'AlessioDA,CoghlanMP,RosenkildeMM,CampbellJE,SloopKW"Tirzepatideis animbalancedandbiaseddualGIPandGLP-1receptoragonist."JCIInsight.2020 Sep3;5(17):e140532.doi:10.1172/jci.insight.140532.PMID:32730231
12NauckMA,D'AlessioDA."Tirzepatide,adualGIP/GLP-1receptorco-agonist forthetreatmentoftype2diabeteswithunmatchedeffectivenessregrading glycaemiccontrolandbodyweightreduction"CardiovascDiabetol2022Sep 1;21(1):169.doi:10.1186/s12933-022-01604-7.PMID:36050763
13SattarN,McGuireDK,PavoI,WeerakkodyGJ,NishiyamaH,WieseRJ, ZoungasS."Tirzepatidecardiovasculareventriskassessment:apre-specified meta-analysis."NatMed.2022Mar;28(3):591-598.doi:10.1038/s41591-022-01707-4.
Epub2022Feb24PMID:35210595
14ForzanoI,VarzidehF,AvvisatoR,JankauskasSS,MoneP,Santulli G."Tirzepatide:ASystematicUpdate."IntJMolSci.2022Nov23;23(23):14631.doi: 10.3390/ijms232314631.PMID:36498958
15FarzamK,PatelP."Tirzepatide."2023May26.In:StatPearls[Internet].Treasure Island(FL):StatPearlsPublishing;2023Jan–PMID:36251836